For years, pharma’s critics have decried the industry’s practice of “evergreening,” or extending drug patent life, arguing that it results in expensive and less innovative products. However, the ...
Strategy Is in Vogue from Large Pharma Companies to Biotechs and Foundations Pharmaceutical companies on average spent $1.1 billion to develop and launch a new drug during the late 1990s, according to ...
Unique approach uses Thomson Reuters drug data and expert analysis to identify repositioning candidates PHILADELPHIA, PA, October 23, 2012 – With more than 2,000 drugs reintroduced for alternative ...
More than six million Americans are living with Alzheimer’s disease (AD), the leading cause of dementia worldwide, and nearly 95 percent of all AD cases are late-onset. However, the current success ...
Drug repurposing is emerging as a strategic approach for treating rare and orphan diseases that have limited treatment options. By repurposing existing drugs, companies can potentially shorten ...
The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...
Janus Kinase inhibitors (JAKis) are approved for the management of several chronic inflammatory diseases, from rheumatic conditions, to dermatological and ...
CHARLOTTESVILLE, Virginia, November 9, 2010 /PRNewswire/ -- Biovista announced today that it has entered into a pilot research collaboration agreement with Pfizer (Pfizer Inc. (NYSE: PFE). The aim of ...
Astellas has turned to Biovista for help finding new indications for some of its existing compounds. The project is underpinned by Biovista's Clinical Outcome Search Space (COSS) technology, a tool ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback